Health
QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial – OncLive
Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Quality of life (QoL) according to patient-reported outcomes (PROs) was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib (Zejula) versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial, according to a subanalysis presented by Bhavana Pothuri, MD, during the ESMO 2020 Virtual Congress.
PRIMA was an ongoing a randomized, double-blind, placebo-controlled phase 3 trial in which patients with newly diagno…
-
Business20 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General21 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
General20 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts
-
Noosa News12 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up